Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to 'look outside the walls of the ...

Charles River Laboratories is permanently closing its pathology facility in Durham, NC, after determining it is no longer “a ...

Sen­ate Fi­nance Com­mit­tee De­moc­rats are call­ing Robert F. Kennedy Jr.’s new di­vest­ment plans to his son “plain­ly ...

Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last ...

Thermo Fisher Scientific is cutting 300 employees across two viral vector manufacturing facilities in Massachusetts, marking ...

GH Research has shared compelling data in people with a traditionally challenging form of depression dosed with its ...

For the first time, the FDA will consider whether to approve a trio of drugs for tiny patient populations based on trials ...

Algiax Pharmaceuticals’ non-opioid candidate has achieved “clinically meaningful” pain reduction in a mid-stage trial of ...

Radiopharmaceuticals biotech AdvanCell has pulled together a $112 million Series C about two years after its much smaller ...

Johnson & Johnson’s subcutaneous form of Rybrevant has been recommended for approval by the European Medicines Agency’s human ...

Pfizer’s Braftovi combo regimen helped prolong the lives of certain patients with previously untreated colorectal cancer, and ...

Tectonic plans $185M private placement after stock swings. Acelyrin returns drug to Affibody. Immunome, 89bio complete offerings. Valneva gets $32.8M DoD contract for Ixiaro vaccine.